Management of Chronic Kidney Disease Stages 1–3
Clinical Bottom Line: Risk for Mortality in Patients With CKD Stages 1–3 Treated With ACEIs or ARBs (1 of 2)
The risk for mortality was not significantly different in patients with CKD stages 1–3 who were treated with a placebo versus an ACEI, an ARB, or an ACEI plus a diuretic. The risk for mortality was also not significantly different in patients with CKD stages 1–3 who were treated with an ACEI versus an ARB, a CCB, or a beta-blocker; an ARB versus a CCB; an ACEI plus an ARB versus an ACEI alone; or an ACEI plus an ARB versus an ACEI or ARB alone.
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CCB = calcium channel blocker; CKD = chronic kidney disease; SOE = strength of evidence
Keywords: ACEI | ARB | cardiovascular disease | CVD | diabetes | microalbuminuria | mortality | outcomes | treatment | chronic kidney disease
- Fink HA, Ishani A, Taylor BC, et al. Chronic Kidney Disease Stages 1–3: Screening, Monitoring, and Treatment. Comparative Effectiveness Review No. 37 (Prepared by the Minnesota Evidence-based Practice Center under Contract No. HHSA 290-2007-10064-I). Rockville, MD: Agency for Healthcare Research and Quality; January 2012. AHRQ Publication No. 11(12)-EHC075-EF. Available at www.effectivehealthcare.ahrq.gov/ckd.cfm.
Your slide tray is being processed.